Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Cancer

Date Submitted: Jul 27, 2020
Date Accepted: Sep 25, 2021
Date Submitted to PubMed: Nov 29, 2021

The final, peer-reviewed published version of this preprint can be found here:

Remote Monitoring of the Performance Status and Burden of Symptoms of Patients With Gastrointestinal Cancer Via a Consumer-Based Activity Tracker: Quantitative Cohort Study

Ghods A, Shahrokni A, Ghasemzadeh H, Cook D

Remote Monitoring of the Performance Status and Burden of Symptoms of Patients With Gastrointestinal Cancer Via a Consumer-Based Activity Tracker: Quantitative Cohort Study

JMIR Cancer 2021;7(4):e22931

DOI: 10.2196/22931

PMID: 34842527

PMCID: 8665393

The remote monitoring of gastrointestinal cancer patients’ performance status and burden of symptoms via a consumer-based activity tracker: qualitative focus group study

  • Alireza Ghods; 
  • Armin Shahrokni; 
  • Hassan Ghasemzadeh; 
  • Diane Cook

ABSTRACT

Background:

Patients with cancer spend most of their time in their homes, but their condition is under constant change as a result of the treatment they receive. Patients' performance status (PS) and their symptoms assessments have typically only been collected during clinic visits. Developing a secure and reliable remote monitoring system is a necessity that can be achieved with an inexpensive consumer-based activity tracker. The real-time data captured by wearable activity trackers could provide a dynamic view of patients for clinicians to make an informed treatment.

Objective:

This study aims to assess the practicality of a consumer-based activity tracker for remote monitoring of gastrointestinal cancer patients.

Methods:

Twenty-seven consenting patients (63% male, median age 58 years) wore a consumer-based activity tracker seven days before chemotherapy, and fourteen days after receiving their first treatment. The clinician assessed patients' ECOG-PS and Memorial Symptom Assessment Checklist-Short Form (MSAS-SF) for patients pre- and post-chemotherapy. The statistical correlation between ECOG-PS and MSAS-SF of patients with their step count was assessed.

Results:

The daily step count had the highest correlation with the patients' ECOG-PS after chemotherapy (P = 6.4e-11). The patients with higher ECOG-PS experienced a higher fluctuation in their step count. The patients who walked more (mean: 6071 steps per day) pre-chemotherapy and (mean: 5930 steps per day) post-chemotherapy had a lower MSAS score (less burden of symptoms) compared to patients who walked less (mean: 5205 steps per day) pre-chemotherapy and (mean: 4437 steps per day) post-chemotherapy.

Conclusions:

This study demonstrates the feasibility of inexpensive, consumer-based activity trackers in monitoring patients’ PS and MSAS in the gastrointestinal cancer population. The findings need to be validated in a larger population for generalizability.


 Citation

Please cite as:

Ghods A, Shahrokni A, Ghasemzadeh H, Cook D

Remote Monitoring of the Performance Status and Burden of Symptoms of Patients With Gastrointestinal Cancer Via a Consumer-Based Activity Tracker: Quantitative Cohort Study

JMIR Cancer 2021;7(4):e22931

DOI: 10.2196/22931

PMID: 34842527

PMCID: 8665393

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.